Indeed, numerous solid and hematopoietic tumors exhibit activation of this pathway following genetic alterations either in upstream signaling molecules, such as receptor tyrosine kinases and oncogenic fusion proteins, or in overexpression of one of the elements of this pathway [2, 3]. The gene discussed is NTRK1; the disease is hematopoietic and lymphoid cell neoplasm.